CATALYSTYahoo • 2d ago
Cencora Gears Up to Report Q4 Results: How to Play the Stock?COR's Q4 earnings are likely to benefit from strong specialty pharma demand and MSO growth, but pricing pressures and higher interest costs may weigh on results.
Why PAHC Stock surged +2.59% Today — RQD Quant Desk Flash
$38.86 +2.59% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
Phibro Animal Health Corporation (Class A) (PAHC) carries a Roarable Rating of C+ (Hold) with 68/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
ROARABLE C+ • HOLD / WATCH
Cap $1.58B
INTERACTIVE SCENARIO DECK:
RQD QUANT TACHOMETERHOLD / WATCH • C+
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw C · Rk B
Each axis scored 0–20
12M PRICE TARGET CONE+4.5% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PAHC)Realized 20D OHLCV Swing Band: ±7.6%
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why PAHC Stock surged +2.59% Today — RQD Quant Desk Flash
Phibro Animal Health Corporation (Class A) (PAHC) surged +2.59% to $38.86, trading at 33% of its 52-week range ($28.25 – $60.08). Solid 31% profit margin (10% return on capital), mixed timing at 33x P/E—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 33% of its 52-week range ($28.25 – $60.08) with RSI-14 at 56.9 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±7.6% around $38.86 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable C+ (Hold) backed by 30.9% gross margin and $80.1M annual free cash flow.
Live PAHC Headlines & Catalysts
CATALYSTYahoo • 2d ago
Revvity Gears Up to Post Q3 Earnings: What's in Store for the Stock?RVTY's Q3 earnings may gain from recovering pharma demand, stronger HCS demand and software growth, despite lingering spending and TB-related headwinds.
CATALYSTYahoo • 2d ago
STERIS Set to Report Q2 Earnings: What's in the Cards for the Stock?STE's second-quarter fiscal 2027 earnings may benefit from Healthcare growth, recent acquisitions, easing AST comparisons and continued margin expansion.
RISK WATCHYahoo • 3d ago
ALGN Q3 Earnings & Revenues Beat, '26 Sales View Down, Stock FallsAlign Technology's Q3 earnings and revenues beat estimates on higher aligner shipments, but a lowered 2026 sales outlook weighs on shares.
CATALYSTYahoo • 3d ago
BTSG Ahead of Q3 Earnings: Can Growth Offset Ongoing IRA Risks?BrightSpring gears up for Q3 earnings, with strong Specialty, Infusion and Provider Services growth expected to offset IRA headwinds. Can it beat estimates?
CATALYSTYahoo • 3d ago
Zimmer Biomet Gears Up to Report Q3 Earnings: What's in the Cards?ZBH heads into Q3 earnings with growth expected in Hips, S.E.T. and Technology & Data, while Knee sales face ongoing pressure.
RISK WATCHYahoo • 3d ago
3 value stocks with warning signsValue stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a
MARKET WIREYahoo • 3d ago
Phibro Animal Health Corporation to Host Webcast and Conference Call on First Quarter ResultsTEANECK, N.J., October 28, 2026--Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its first quarter financial results on Wednesday, November 4, 2026, after the market closes. Phibro management will hos
RISK WATCHYahoo • 4d ago
UHS Misses Q3 Earnings Estimates Despite Higher Patient VolumesUniversal Health Services' Q3 earnings fall 8.3% despite revenue growth, as rising costs and Acute Care pricing pressure offset higher patient volumes.
CATALYSTYahoo • 4d ago
Waters Gears Up to Report Q3 Results: How to Play the Stock?WAT's Q3 results are likely to benefit from strong revenue growth prospects, rising demand and acquisition gains.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (PAHC Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
PAHC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -26.93%⚡ TESTING RESISTANCE
2026-10-30O $39.38H $39.95L $38.49C $38.86VOL 182.8K
RES: $40.91SUP: $34.09SMA50: $36.99SMA200: $41.26
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
PAHC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
25.3%/yr Implied 5Y Growth
vs. +27.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on PAHC today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for PAHC. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PAHC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PAHC)
Health Care Rank #108 of 1016
⚔️ GPCR vs PAHC Full Matrix →
1. Head-to-Head Health Care Peer Comparison (PAHC vs. GPCR, OCUL, INVA, ETON)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Phibro Animal Health Corporation (Class A) (PAHC) ranks #108 by composite RQD confidence (68/100, grade C+) and #300 by equity capitalization ($1.58B). Within this direct 5-issuer industry benchmark cohort, PAHC leads on earnings valuation at 32.7x trailing P/E, while INVA leads on capital efficiency and profitability with 14.7% ROIC and 74.8% gross margin. INVA currently holds the highest overall quantitative score in the immediate peer group at 75/100 (B) compared with PAHC at 68/100 (C+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PAHC
ACTIVE
Phibro Animal Health Corporation (Class A) | C+ | 68/100 | 32.7x | 30.9% | 9.9% | +2.59% | $1.58B | Benchmark Subject |
| GPCR Structure Therapeutics Inc. | D- | 42/100 | — | — | -19.5% | +2.14% | $1.56B | /gpcr-vs-pahc → |
| OCUL Ocular Therapeutix Inc. | D- | 37/100 | — | 87.3% | -35.0% | +0.27% | $1.61B | /ocul-vs-pahc → |
| INVA Innoviva Inc. | B | 75/100 | — | 74.8% | 14.7% | +0.90% | $1.54B | /inva-vs-pahc → |
| ETON Eton Pharmaceuticals Inc. | C | 62/100 | — | 53.5% | -0.9% | +3.61% | $1.53B | /eton-vs-pahc → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001069899In its most recent audited fiscal period (FY2025, filed 2025-06-30), Phibro Animal Health Corporation (Class A) (PAHC) reported GAAP revenue of $1.30B (+27.4% vs. FY2024 revenue of $1.02B , and +32.6% cumulative change since FY2023) , GAAP net income of $48.3M, operating cash flow of $80.1M, and free cash flow of $80.1M (-8.5% YoY). On the balance sheet, PAHC closed FY2025 with $1.41B in total assets against $603.6M in total debt (Altman Z-Score: 2.87, Piotroski F-Score: 8/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-06-30 | $1.30B | $48.3M | $80.1M | $80.1M | $1.41B | $603.6M |
| FY2024 (FY) | 2024-06-30 | $1.02B | $2.4M | $87.6M | $87.6M | $1.29B | $622.9M |
| FY2023 (FY) | 2023-06-30 | $977.9M | $32.6M | $13.3M | $13.3M | — | — |
3. PAHC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs PAHC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Phibro Animal Health Corporation (Class A) (NASDAQ: PAHC) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 68/100 at a spot price of $38.86 (+2.59% 1D, market cap $1.58B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 14/20. Across 1016 tracked Health Care issuers, PAHC ranks #108 in composite RQD confidence.
How does PAHC compare to GPCR and OCUL in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PAHC carries a Roarable C+ (68/100 RQD), trailing P/E of 32.7x, gross margin of 30.9%, and ROIC of 9.9%. By comparison, GPCR (Structure Therapeutics Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -19.5%, cap $1.56B) and OCUL (Ocular Therapeutix Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $1.61B). Among the 5-stock peer group, PAHC leads on earnings multiple (32.7x) while INVA leads on capital efficiency (14.7% ROIC).
What are the biggest fundamental strengths and SEC risk factors for PAHC?
Per PAHC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001069899), Phibro Animal Health Corporation (Class A) generated $1.30B in revenue (+27.4% YoY), $48.3M in net income, and $80.1M in free cash flow against $1.41B in total assets and $603.6M in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is PAHC trading relative to its 50-day, 200-day, and 52-week technical levels?
PAHC last traded at $38.86 (+2.59% on volume of 100,844 shares), positioning the stock +5.06% above its 50-day simple moving average ($36.99) and -5.82% below its 200-day simple moving average ($41.26). Across its 52-week range of $28.25 to $60.08, PAHC sits at the 33.3% percentile with a 14-day RSI of 56.9 (BULLISH MOMENTUM) and an implied next-earnings move of ±7.6% ($35.91 to $41.81).
PAHC Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is PAHC stock moving today?
Why PAHC Stock surged +2.59% Today — RQD Quant Desk Flash. Solid 31% profit margin (10% return on capital), mixed timing at 33x P/E—hold if owned, no rush to chase.